ADVAGEN, a Singapore based company founded in 2006 which develops and markets healthcare supplements and pharmaceuticals, is pleased to announce its chemotherapeutic product, Irinotecan ADVAGEN, is now approved in Singapore.

“We are extremely pleased to receive the registration approval for Irinotecan ADVAGEN. It was a challenging process but knowing the benefits it provides to patients in Singapore makes it all worthwhile.” – Koh, Director of ADVAGEN